Graham Capital Management’s Kronos Bio KRON Stock Holding History

Graham Capital Management’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-91,582	Closed	-$333K	–	1186
2022 Q2	$333K	Buy	+91,582	New	+$415K	0.01%	791

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Graham Capital Management's KRON Position: Q3 2022 in Review

Graham Capital Management sold out of Kronos Bio (KRON) in Q3 2022, closing a stake of 91,582 shares — an estimated $333K sold.

Graham Capital Management first reported a position in KRON in Q2 2022 and held it in 1 quarter. The position peaked at $333K in Q2 2022. 96 funds tracked by Wall St. Rank hold KRON as of Q3 2022.

Graham Capital Management reported no remaining Kronos Bio position as of Q3 2022 after selling out during the quarter.
Graham Capital Management sold 91,582 Kronos Bio shares in Q3 2022, an estimated $333K.
Graham Capital Management first reported a position in Kronos Bio in Q2 2022 and held it in 1 quarter.
Graham Capital Management's Kronos Bio position peaked at $333K in Q2 2022.
96 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2022.

Based on Graham Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.